Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Arena jumps on resubmission of NDA for weight-loss drug

This article was originally published in Scrip

Executive Summary

After the markets closed on 3 January, Arena Pharmaceuticals and its partner Eisai revealed they had submitted new data last week to the US FDA to address the agency's October 2010 complete response letter (CRL) rejecting the firms' new drug application (NDA) for their experimental weight loss drug lorcaserin.



Related Companies